Literature DB >> 11266389

Prevention of pancreatic cancer induction in hamsters by metformin.

M B Schneider1, H Matsuzaki, J Haorah, A Ulrich, J Standop, X Z Ding, T E Adrian, P M Pour.   

Abstract

BACKGROUND AND AIMS: Our previous study suggested that the known promotional effect of a high fat diet, which in hamsters induces peripheral insulin resistance, is related to a compensatory proliferation of islet cells. The present study was to examine whether the prevention of islet cell proliferation can inhibit the promotional effect of a high-fat diet in pancreatic carcinogenesis.
METHODS: Two groups of high fat-fed hamsters were used. One group received Metformin in drinking water for life (HF+Met group), and the other group served as a control (HF group). At the time when the normalization of the plasma insulin level was expected, all hamsters were treated with the pancreatic carcinogen, N-nitrosobis-(2-oxopropyl)amine, and the experiment was terminated 42 weeks later.
RESULTS: Although 50% of the hamsters in the high-fat group developed malignant lesions, none was found in the HF+Met group (P < 0.05). Also, significantly more hyperplastic and premalignant lesions, most of which were found within the islets, were detected in the high-fat group (8.6 lesions/hamster) than in the HF+Met group (1.8 lesions/hamster).
CONCLUSIONS: The results lend further support on the significant role of islet cells in pancreatic carcinogenesis and may explain the association between pancreatic cancer and obesity, which is usually associated with peripheral insulin resistance.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11266389     DOI: 10.1053/gast.2001.23258

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  120 in total

Review 1.  Pancreatic ductal adenocarcinoma: a review of immunologic aspects.

Authors:  Megan B Wachsmann; Laurentiu M Pop; Ellen S Vitetta
Journal:  J Investig Med       Date:  2012-04       Impact factor: 2.895

2.  Diabetes and pancreatic cancer.

Authors:  Donghui Li
Journal:  Mol Carcinog       Date:  2012-01       Impact factor: 4.784

Review 3.  Chemoprevention strategies for pancreatic cancer.

Authors:  Silvia D Stan; Shivendra V Singh; Randall E Brand
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2010-05-04       Impact factor: 46.802

4.  Untuning the tumor metabolic machine: Targeting cancer metabolism: a bedside lesson.

Authors:  Kıvanç Birsoy; David M Sabatini; Richard Possemato
Journal:  Nat Med       Date:  2012-07-06       Impact factor: 53.440

5.  New strategies in pancreatic cancer: emerging epidemiologic and therapeutic concepts.

Authors:  Donghui Li; James L Abbruzzese
Journal:  Clin Cancer Res       Date:  2010-07-20       Impact factor: 12.531

6.  Metformin Restrains Pancreatic Duodenal Homeobox-1 (PDX-1) Function by Inhibiting ERK Signaling in Pancreatic Ductal Adenocarcinoma.

Authors:  G Zhou; J Yu; A Wang; S-H Liu; J Sinnett-Smith; J Wu; R Sanchez; J Nemunaitis; C Ricordi; E Rozengurt; F C Brunicardi
Journal:  Curr Mol Med       Date:  2016       Impact factor: 2.222

7.  Metformin suppresses pancreatic tumor growth with inhibition of NFκB/STAT3 inflammatory signaling.

Authors:  Xiang-Lin Tan; Kalyan K Bhattacharyya; Shamit K Dutta; William R Bamlet; Kari G Rabe; Enfeng Wang; Thomas C Smyrk; Ann L Oberg; Gloria M Petersen; Debabrata Mukhopadhyay
Journal:  Pancreas       Date:  2015-05       Impact factor: 3.327

8.  Advances in Pancreatic Cancer, Intraductal Papillary Mucinous Neoplasms, and Pancreatitis.

Authors:  Santhi Swaroop Vege; Stephen J Pandol
Journal:  Gastroenterology       Date:  2018-08-02       Impact factor: 22.682

Review 9.  Diabetes mellitus: a risk factor for pancreatic cancer?

Authors:  M Yalniz; P M Pour
Journal:  Langenbecks Arch Surg       Date:  2004-04-09       Impact factor: 3.445

10.  Diabetes mellitus as a risk factor for gastrointestinal cancer among American veterans.

Authors:  M Mazen Jamal; Eugene J Yoon; Kenneth J Vega; Mehrtash Hashemzadeh; Kenneth J Chang
Journal:  World J Gastroenterol       Date:  2009-11-14       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.